Glucagon News and Research

RSS

Body image concerns drive interest in GLP-1 weight loss drugs, study finds

A new study from Rutgers University links higher body dissatisfaction, BMI, and maladaptive weight loss behaviors with interest in GLP-1 medications for weight loss. Conversely, body appreciation appears to protect against this interest, especially in the face of potential side effects.

23 Apr 2025

Diabetes drugs GLP-1RA and SGLT2i lower dementia risk in older adults, study finds

A large population-based study found that GLP-1 receptor agonists (GLP-1RAs) and SGLT2 inhibitors (SGLT2is), two classes of glucose-lowering drugs used in type 2 diabetes, were associated with a significantly reduced risk of Alzheimer’s disease and related dementias (ADRD). These findings suggest potential neuroprotective benefits and highlight drug repurposing as a promising strategy for ADRD prevention.

21 Apr 2025

Study: Women show greater awareness of obesity drugs than men

New research to be presented at this year's European Congress on Obesity (ECO 2025, Malaga, Spain, 11-14 May) shows that women are much more aware of knowledgeable about the obesity drugs GLP-1/GIP receptor agonists (that include semaglutide and tirzepatide).

17 Apr 2025

GLP1 agonists linked to depression risk in new genetic study

A groundbreaking study published in the journal Current Neuropharmacology highlights a concerning potential link between Glucagon-like Peptide-1 (GLP1) receptor agonists-widely used in blockbuster drugs like Ozempic-and the risk of depression and suicidal ideation (SI).

17 Apr 2025

New Canadian guidelines offer comprehensive approach to managing pediatric obesity

Researchers provide evidence-based recommendations to manage pediatric obesity.

17 Apr 2025

Diabetes medications may help shield the brain from cognitive decline

A study led by researchers in the University of Florida College of Pharmacy has found that a pair of popular glucose-lowering medications may have protective effects against the development of Alzheimer's disease and related dementias in patients with Type 2 diabetes.

16 Apr 2025

GLP-1 agonists may reshape the gut microbiome

Research reveals GLP-1 receptor agonists influence gut microbiome, enhancing metabolic health and offering anti-inflammatory benefits for diabetes management.

11 Apr 2025

Study shows minimal lean muscle mass loss with GLP-1 and GLP-1/GIP therapy for weight loss

New research to be presented at this year's European Congress on Obesity (ECO 2025, Malaga, Spain, 11-14 May) shows that patients using GLP-1 or combined GLP-1 / GIP receptor agonist therapy for weight loss experienced minimal lean muscle mass loss as they lost weight across 6 months of treatment.

9 Apr 2025

Semaglutide linked to higher risk of vision problems, FDA data analysis shows

Researchers from the University of Bern analyzed over 300,000 FDA reports and found semaglutide use was linked to a higher reporting rate of vision impairment. The findings call for further study into the ocular risks of this widely prescribed diabetes and weight loss drug.

8 Apr 2025

Rare sugars curb appetite and mimic diabetes drugs in mice

Rare sugars like D-allulose, D-tagatose, and D-sorbose significantly boosted GLP-1 secretion and suppressed food intake in mice. D-allose also reduced food intake through a unique, GLP-1-independent pathway.

1 Apr 2025

New trial shows oral semaglutide reduces cardiovascular events in diabetes patients

Both the injectable and oral forms of semaglutide, a glucagon-like peptide-1 receptor agonist, have gained recent attention for their effectiveness against weight gain, high blood sugar, and even alcohol cravings.

31 Mar 2025

Why sucralose could make you hungrier instead of helping you lose weight

Sucralose increases hypothalamic activity linked to hunger more than sugar or water, especially in women and people with obesity.

30 Mar 2025

Semaglutide improves maximal walking distance in people with symptomatic PAD and Type 2 diabetes

Semaglutide, a glucagon-like peptide 1 (GLP-1) agonist, significantly improved maximal walking distance in people with symptomatic peripheral artery disease (PAD) and Type 2 diabetes in the first-of-its kind trial to evaluate the use of a GLP-1 agonist to manage PAD.

29 Mar 2025

Unveiling leptin signaling in the DMH for metabolic effects

Scientists at Pennington Biomedical Research Center have gained greater clarity in the brain regions and neurons that control metabolism, body temperature and energy use.

27 Mar 2025

Common sugar substitute increases activity in the brain's hypothalamus

Compared to sugar, consuming sucralose-a widely used sugar substitute-increases activity in the hypothalamus, a brain region that regulates appetite and body weight, according to a new USC study.

26 Mar 2025

Flavonoids help regulate gut hormones and show promise in managing type 2 diabetes

Flavonoids show promise in treating type 2 diabetes mellitus by targeting the enteroendocrine system and regulating key gut hormones. They enhance insulin sensitivity, reduce oxidative stress, and influence appetite, glucose uptake, and hormone secretion.

26 Mar 2025

Exploring the therapeutic potential of flavonoids in type 2 diabetes

Type 2 diabetes mellitus (T2DM) is a chronic metabolic disorder with a rapidly increasing global prevalence. It is primarily characterized by insulin resistance, β-cell dysfunction, and impaired glucose homeostasis.

20 Mar 2025

Biomanufacturing platform offers a sustainable alternative to synthesizing peptide-based pharmaceuticals

To tackle the inequity in medication access, a societal issue especially in developing nations, a team of undergraduate student-researchers at the University of Ottawa has developed a new biomanufacturing platform called Phytogene.

18 Mar 2025

Novel cyclic peptide antagonist can be a promising therapeutic approach for MASH

The farnesoid X receptor (FXR) is a bile acid nuclear receptor that plays a crucial role in regulating bile acid and sterol metabolism.

14 Mar 2025

Tirzepatide helps people without diabetes lose 13% body weight in real-world study

A real-world study of over 4,000 US patients without type 2 diabetes found that those who persisted with Tirzepatide for at least six months lost an average of 12.9% of their body weight. The study highlights Tirzepatide’s potential as an effective off-label obesity treatment before its formal FDA approval for weight loss.

11 Mar 2025

Glucagon News and Research

Body image concerns drive interest in GLP-1 weight loss drugs, study finds

Diabetes drugs GLP-1RA and SGLT2i lower dementia risk in older adults, study finds

Study: Women show greater awareness of obesity drugs than men

GLP1 agonists linked to depression risk in new genetic study

New Canadian guidelines offer comprehensive approach to managing pediatric obesity

Diabetes medications may help shield the brain from cognitive decline

GLP-1 agonists may reshape the gut microbiome

Study shows minimal lean muscle mass loss with GLP-1 and GLP-1/GIP therapy for weight loss

Semaglutide linked to higher risk of vision problems, FDA data analysis shows

Rare sugars curb appetite and mimic diabetes drugs in mice

New trial shows oral semaglutide reduces cardiovascular events in diabetes patients

Why sucralose could make you hungrier instead of helping you lose weight

Semaglutide improves maximal walking distance in people with symptomatic PAD and Type 2 diabetes

Unveiling leptin signaling in the DMH for metabolic effects

Common sugar substitute increases activity in the brain's hypothalamus

Flavonoids help regulate gut hormones and show promise in managing type 2 diabetes

Exploring the therapeutic potential of flavonoids in type 2 diabetes

Biomanufacturing platform offers a sustainable alternative to synthesizing peptide-based pharmaceuticals

Novel cyclic peptide antagonist can be a promising therapeutic approach for MASH

Tirzepatide helps people without diabetes lose 13% body weight in real-world study

Industry Focus eBook - Forensics & toxicology (2nd edition) eBook

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Latest News